Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677880 · ClinicalTrials.gov registry record
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
A clinical trial of CADASIL, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- 660
- Enrollment target
- 12
- Study locations
NCT05677880: Recruiting study of CADASIL, sponsored by University of Wisconsin, Madison.
NCT05677880 is a study of CADASIL that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 660 participants. The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05677880, a study of CADASIL, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- 660 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
Primary Outcome
A composite Cognitive Executive Function Score will be reported based on data from two electronic assessments (Favorites and Match). Favorites tests both episodic and associative memory and consists of 2 learning trials followed by an immediate recall trial, 10 minute delayed recall, and delayed recognition trials. The Match assessment tests the processing speed and executive functions. The primary performance metric is the total correct score in 2 minutes. Scores are reported on a continuous sc
Conditions Studied
Interventions
- OTHER Study Procedures
Study Locations (12)
California
- University of California - Los Angeles
- University of California - San Francisco
Texas
- University of Texas Health Science Center - Houston
- University of Texas - San Antonio
Colorado
- University of Colorado - Denver
Georgia
- Georgia State University Research Foundation - Atlanta
Illinois
- Loyola University - Chicago
New York
- Columbia University - New York
Oregon
- Oregon Health & Science University - Portland
Rhode Island
- Brown University - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2027-08 |
What NCT05677880 shows while recruiting
NCT05677880 is an observational study that tracks outcomes without assigning an intervention. The registered 660 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with CADASIL appearing as the primary indexed condition, and to 1 intervention - of which Study Procedures is the first listed.
NCT05677880 lists 12 locations in 10 states (California, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT05677880 about?
NCT05677880 is a clinical study titled "Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study". This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.
What is the current status of trial NCT05677880?
This trial is currently recruiting. The enrollment target is 660 participants. The study started on 2022-06-03. Estimated completion is 2027-08.
What conditions does trial NCT05677880 study?
This clinical trial studies the following conditions: CADASIL.
What interventions are being tested in trial NCT05677880?
The interventions under investigation include: Study Procedures (OTHER).
Who is sponsoring clinical trial NCT05677880?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05677880 being conducted?
This trial has 12 study locations across California, Colorado, Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CADASIL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
- NCT05470205 · 660 participants · Phase 3
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI